title: Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.
abstract: The intent of cancer immunotherapy (CIT) is to generate and enhance T-cell responses against tumors. The tumor microenvironment establishes several inhibitory pathways that lead to suppression of the local immune response, which is permissive for tumor growth. The efficacy of different CITs, alone and in combination, stems from reinvigorating the tumor immune response via several mechanisms, including costimulatory agonists, checkpoint inhibitors, and vaccines. However, immune responses to other antigens (self and foreign) may also be enhanced, resulting in potentially undesired effects. In outbred mammalian pregnancies, the fetus expresses paternally derived alloantigens that are recognized as foreign by the maternal immune system. If unchecked or enhanced, maternal immunity to these alloantigens represents a developmental and reproductive risk and thus is a general liability for cancer immunotherapeutic molecules. We propose a tiered approach to confirm this mechanistic reproductive liability for CIT molecules. A rodent allopregnancy model is based on breeding 2 different strains of mice so that paternally derived alloantigens are expressed by the fetus. When tested with a cross-reactive biotherapeutic, small molecule drug, or surrogate molecule, this model should reveal on-target reproductive liabilities if the pathway is involved in maintaining pregnancy. Alternatively, allopregnancy models with genetically modified mice can be interrogated for exquisitely specific biotherapeutics with restricted species reactivity. The allopregnancy model represents a relatively straightforward approach to confirm an expected on-target reproductive risk for CIT molecules. For biotherapeutics, it could potentially replace more complex developmental and reproductive toxicity testing in nonhuman primates when a pregnancy hazard is confirmed or expected.
authors.affiliation: Department of Safety Assessment, Genentech Inc, South San Francisco, CA, USA prell.rodney@gene.com.
authors.forename: Rodney A
authors.initials: RA
authors.lastname: Prell
authors.affiliation: Department of Safety Assessment, Genentech Inc, South San Francisco, CA, USA.
authors.forename: Wendy G
authors.initials: WG
authors.lastname: Halpern
authors.affiliation: Department of Safety Assessment, Genentech Inc, South San Francisco, CA, USA.
authors.forename: Gautham K
authors.initials: GK
authors.lastname: Rao
mesh_terms: D000818:Animals; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D005260:Female; D007167:Immunotherapy / Q000009:adverse effects*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors; D051379:Mice; D023421:Models, Animal; D009369:Neoplasms / Q000628:therapy*; D011247:Pregnancy; D012098:Reproduction / Q000187:drug effects; D018675:Toxicity Tests / Q000379:methods*
chemical_list: D060890:B7-H1 Antigen; C498919:Cd274 protein, mouse; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase
keywords: allopregnancy; immunotherapy; maternal–fetal; reproductive; tolerance